Who
Theodore Alan Huizenga
SVP, Chief Accounting Officer
Company insider
Files Form 4 as: SVP, Chief Accounting Officer, Ultragenyx Pharmaceutical.
In numbers
- Trades disclosed
- 138
- Buys
- 0
- Sells
- 36
- Bought
- $0
- Sold
- $3.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Mar 2015
- Last trade
- 15 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 15 Sep 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $17K1,283 at $13.57 | filing |
| 15 Sep 2026filed 15 Sep 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $17K1,283 at $13.57 | filing |
| 3 Sep 2026filed 8 Sep 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $2,252161 at $13.99 | filing |
| 3 Sep 2026filed 8 Sep 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $2,252161 at $13.99 | filing |
| 22 Apr 2026filed 24 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —20,241 at $0.00 | filing |
| 22 Apr 2026filed 24 Apr 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —7,348 at $0.00 | filing |
| 22 Apr 2026filed 24 Apr 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —7,348 at $0.00 | filing |
| 22 Apr 2026filed 24 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —20,241 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code F | $3,462148 at $23.39 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $37K1,632 at $22.80 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code F | $3,462148 at $23.39 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $37K1,632 at $22.80 | filing |
| 29 Dec 2025filed 30 Dec 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $2,92285 at $34.38 | filing |
| 18 Sep 2025filed 19 Sep 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $1,86764 at $29.17 | filing |
| 5 Sep 2025filed 8 Sep 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $2,63784 at $31.39 | filing |
| 3 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $41K967 at $42.10 | filing |
| 3 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code F | $6,052141 at $42.92 | filing |
| 1 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —5,632 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —9,392 at $0.00 | filing |
| 10 Dec 2024filed 11 Dec 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code G | —648 at $0.00 | filing |
News
Ultragenyx Pharmaceutical (NASDAQ:RARE) CAO Theodore Alan Huizenga Sells 1,283 Sharesdailypolitical.com · 16 Sep 2026Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026
1 headline in the last 90 days name Theodore Alan Huizenga; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.